<code id='0180A238A0'></code><style id='0180A238A0'></style>
    • <acronym id='0180A238A0'></acronym>
      <center id='0180A238A0'><center id='0180A238A0'><tfoot id='0180A238A0'></tfoot></center><abbr id='0180A238A0'><dir id='0180A238A0'><tfoot id='0180A238A0'></tfoot><noframes id='0180A238A0'>

    • <optgroup id='0180A238A0'><strike id='0180A238A0'><sup id='0180A238A0'></sup></strike><code id='0180A238A0'></code></optgroup>
        1. <b id='0180A238A0'><label id='0180A238A0'><select id='0180A238A0'><dt id='0180A238A0'><span id='0180A238A0'></span></dt></select></label></b><u id='0180A238A0'></u>
          <i id='0180A238A0'><strike id='0180A238A0'><tt id='0180A238A0'><pre id='0180A238A0'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:2998
          Several amyloid plaques forming between neurons in a brain
          Amyloid plaques forming between neurons. Adobe

          The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

          The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

          advertisement

          Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          How to use technology to prevent future drug shortages
          How to use technology to prevent future drug shortages

          TherehasbeenapersistentshortageoftheADHDdrugAdderall.JennyKane/APMyfirstexposuretopharmaceuticalshor

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

          FloridaStateUniversityscientistsarestudyinghowmalezebrafincheslearntosing.MohammadAbdullah/CreativeC